Ascendis Pharma A (ASND) Assets Average (2013 - 2026)
Ascendis Pharma A (ASND) posted Assets Average of $1.9 billion for Q1 2026, up 34.73% sequentially from $1.4 billion in Q4 2025, and down 13.75% YoY from $2.2 billion in Q1 2025.
Ascendis Pharma A (ASND) Assets Average (2013 - 2026) Analysis & Trends
Ascendis Pharma A has reported Assets Average for 13 years, with the latest figure at $1.9 billion in Q1 2026.
- Quarterly Assets Average fell 13.75% year-over-year to $1.9 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.9 billion (down 13.75% YoY) and the FY2025 annual result came in at $2.4 billion, up 14.65% from the prior year.
- Assets Average climbed to $1.9 billion in Q1 2026 per ASND's latest filing, from $1.4 billion in the prior quarter.
- Over five years, Assets Average peaked at $2.3 billion in Q4 2024 and troughed at $844.2 million in Q2 2024.
- A 5-year average of $1.3 billion and a median of $1.2 billion in 2022 frame the typical range for Assets Average.
- The sharpest annual moves came in 2023 and 2025: Assets Average plunged 43.91% in 2023, then jumped 154.39% in 2025.
- Over 5 years, Assets Average stood at $1.2 billion in 2022, then dropped by 23.25% to $919.4 million in 2023, then soared by 148.1% to $2.3 billion in 2024, then plunged by 37.17% to $1.4 billion in 2025, then surged by 34.73% to $1.9 billion in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $1.9 billion, $1.4 billion, and $1.3 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Ascendis Pharma A | 15.40 Bn | 14.73 Bn | 268.20 Mn | 1.93 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.93 Bn |
| Dec 31, 2025 | 1.43 Bn |
| Sep 30, 2025 | 1.29 Bn |
| Jun 30, 2025 | 1.17 Bn |
| Mar 31, 2025 | 2.24 Bn |
| Dec 31, 2024 | 2.28 Bn |
| Sep 30, 2024 | 1.01 Bn |
| Jun 30, 2024 | 844.21 Mn |
| Mar 31, 2024 | 880.05 Mn |
| Dec 31, 2023 | 919.43 Mn |
| Sep 30, 2023 | 923.83 Mn |
| Jun 30, 2023 | 967.11 Mn |
| Mar 31, 2023 | 1.07 Bn |
| Dec 31, 2022 | 1.20 Bn |
| Sep 30, 2022 | 1.35 Bn |
| Jun 30, 2022 | 1.48 Bn |
| Mar 31, 2022 | 1.92 Bn |
| Dec 31, 2021 | 1.85 Bn |
| Sep 30, 2021 | 1.22 Bn |
| Jun 30, 2021 | 1.10 Bn |